NewAmsterdam Pharma Company NV (NAMS): Next-Year EPS Estimate 26.38%
As of 2026-05-07, NewAmsterdam Pharma Company NV (NAMS) has a next-year EPS growth estimate of 26.38%.
On 2026-05-07, analyst consensus for NAMS's next-year EPS growth shifted from 27.41% to 26.38% — a negative change of 1.03 percentage points. Current-year growth is projected at -8.16%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 26.38%
- EPS growth this year
- -8.16%
- EPS next quarter (est)
- -$0.46
- Last price
- $34.85
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-05-07 | 26.38% | -8.16% | -$0.46 | $34.85 |
| 2026-05-06 | 27.41% | -11.19% | -$0.49 | $30.99 |
| 2026-05-05 | 27.41% | -11.19% | -$0.49 | $29.85 |
| 2026-05-04 | 27.41% | -11.19% | -$0.49 | $29.86 |
| 2026-05-03 | 27.41% | -11.19% | -$0.49 | $28.43 |
| 2026-04-30 | 27.41% | -11.19% | -$0.49 | $28.56 |
| 2026-04-29 | 27.41% | -11.19% | -$0.49 | $28.43 |
| 2026-04-28 | 27.41% | -11.11% | -$0.49 | $28.72 |
| 2026-04-27 | 27.41% | -11.11% | -$0.49 | $30.45 |
| 2026-04-26 | 27.41% | -11.11% | -$0.49 | $29.72 |
| 2026-04-24 | 27.41% | -11.11% | -$0.49 | $29.72 |
| 2026-04-23 | 27.41% | -11.11% | -$0.49 | $31.46 |
| 2026-04-22 | 27.41% | -11.11% | -$0.49 | $31.94 |
| 2026-04-21 | 27.41% | -11.11% | -$0.49 | $32.48 |
| 2026-04-20 | 27.41% | -11.11% | -$0.49 | $33.82 |
| 2026-04-19 | 27.41% | -11.11% | -$0.49 | $34.68 |
| 2026-04-16 | 27.41% | -11.11% | -$0.49 | $33.20 |
| 2026-04-15 | 27.41% | -11.11% | -$0.49 | $34.01 |
| 2026-04-14 | 27.41% | -11.11% | -$0.49 | $34.44 |
| 2026-04-13 | 27.44% | -11.17% | -$0.49 | $36.25 |
| 2026-04-12 | 27.44% | -11.17% | -$0.49 | $34.76 |
| 2026-04-10 | 27.44% | -11.17% | -$0.49 | $34.68 |
| 2026-04-09 | 27.44% | -11.17% | -$0.49 | $35.07 |
| 2026-04-08 | 27.44% | N/A | -$0.49 | $34.01 |
| 2026-04-07 | 27.44% | N/A | -$0.49 | $33.91 |
| 2026-04-06 | 27.44% | N/A | -$0.49 | $33.91 |
| 2026-04-05 | 27.44% | N/A | -$0.49 | $32.99 |
| 2026-04-03 | 27.44% | N/A | -$0.49 | $33.91 |
| 2026-04-02 | 27.44% | N/A | -$0.49 | $33.91 |
| 2026-04-01 | 27.44% | N/A | -$0.49 | $33.91 |
Screen Performance
Aggregate stats across all 1781 tickers our top-EPS-revision screen has flagged over the past 71 days.
- Median return since detection
- +3.8%
- % of tickers in the green
- 58%
- Median return on winners
- +18.5%
- Large revisions captured
- 788
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is NewAmsterdam Pharma Company NV's next-year EPS growth estimate?▾
As of 2026-05-07, NewAmsterdam Pharma Company NV (NAMS) has a next-year EPS growth estimate of 26.38%, based on analyst consensus.
When was the latest EPS estimate revision for NAMS?▾
The most recent revision occurred on 2026-05-07, when analysts adjusted the next-year EPS growth estimate from 27.41% to 26.38%.
What sector and industry does NewAmsterdam Pharma Company NV belong to?▾
NewAmsterdam Pharma Company NV operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. NAMS appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. NewAmsterdam Pharma Company NV (NAMS) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports